PMID- 29122934
OWN - NLM
STAT- MEDLINE
DCOM- 20190301
LR  - 20191210
IS  - 1557-3265 (Electronic)
IS  - 1078-0432 (Print)
IS  - 1078-0432 (Linking)
VI  - 24
IP  - 1
DP  - 2018 Jan 1
TI  - Genotyping Natural Killer Immune Checkpoints to Discover Biomarkers of Response.
PG  - 3-5
LID - 10.1158/1078-0432.CCR-17-2884 [doi]
AB  - Immune checkpoints have been a focus of immunotherapy in the recent decade. 
      Killer cell immunoglobulin-like receptors (KIR) and their cognate human leukocyte 
      antigen (HLA) class I ligands have evolved as checkpoints to ensure 
      self-tolerance of natural killer cells. Both KIR and HLA genetic profiles are 
      potential biomarkers of immunotherapy outcome. Clin Cancer Res; 24(1); 3-5. (c)2017 
      AACRSee related article by Erbe et al., p. 189.
CI  - (c)2017 American Association for Cancer Research.
FAU - Cheung, Nai-Kong
AU  - Cheung NK
AD  - Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New 
      York. cheungn@mskcc.org.
FAU - Hsu, Katharine C
AU  - Hsu KC
AD  - Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New 
      York.
LA  - eng
GR  - P30 CA008748/CA/NCI NIH HHS/United States
GR  - R01 CA164365/CA/NCI NIH HHS/United States
GR  - R01 CA182526/CA/NCI NIH HHS/United States
GR  - R01 FD005415/FD/FDA HHS/United States
PT  - Comment
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20171109
PL  - United States
TA  - Clin Cancer Res
JT  - Clinical cancer research : an official journal of the American Association for 
      Cancer Research
JID - 9502500
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Biomarkers)
RN  - 0 (HLA-C Antigens)
RN  - 0 (Ligands)
RN  - 0 (Receptors, KIR)
RN  - 7SQY4ZUD30 (dinutuximab)
SB  - IM
CON - Clin Cancer Res. 2018 Jan 1;24(1):189-196. PMID: 28972044
MH  - Antibodies, Monoclonal
MH  - Biomarkers
MH  - Child
MH  - *Genotype
MH  - HLA-C Antigens/genetics
MH  - Humans
MH  - Immunotherapy
MH  - Killer Cells, Natural/immunology
MH  - Ligands
MH  - *Neuroblastoma
MH  - Receptors, KIR/genetics
PMC - PMC5754255
MID - NIHMS918824
COIS- Potential Conflict of Interest Declaration Both MSK and NKC have financial 
      interest in Y-mAbs Therapeutics.
EDAT- 2017/11/11 06:00
MHDA- 2019/03/02 06:00
PMCR- 2019/01/01
CRDT- 2017/11/11 06:00
PHST- 2017/10/13 00:00 [received]
PHST- 2017/10/31 00:00 [revised]
PHST- 2017/11/07 00:00 [accepted]
PHST- 2017/11/11 06:00 [pubmed]
PHST- 2019/03/02 06:00 [medline]
PHST- 2017/11/11 06:00 [entrez]
PHST- 2019/01/01 00:00 [pmc-release]
AID - 1078-0432.CCR-17-2884 [pii]
AID - 10.1158/1078-0432.CCR-17-2884 [doi]
PST - ppublish
SO  - Clin Cancer Res. 2018 Jan 1;24(1):3-5. doi: 10.1158/1078-0432.CCR-17-2884. Epub 
      2017 Nov 9.